Renalytix to Present at 42nd Annual William Blair Growth Stock Conference

06.08.22

NEW YORK and SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

06.06.22

Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease NEW YORK and SALT LAKE CITY,

Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®

06.02.22

Real-world clinical utility in 1,112 patients tested with KidneyIntelX KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients NEW YORK and SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its

Renalytix plc successful completion of $30.0 million financing package

04.08.22

Director/PDMR Dealing NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY

Renalytix plc Issue of shares

NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to

Renalytix announces a $30.0 million financing package

03.31.22

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

03.30.22

NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced that, following the Company’s announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix.   As an

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

03.29.22

KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched electronic health records from multiple centers across the U.S. NEW YORK and SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the

Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31

03.25.22

NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 financial results on Thursday, March 31, 2022, before market open.